parco eolico - Le Fonti New Pharma Italy https://www.newpharmaitaly.it/tag/parco-eolico/ Il portale delle news in ambito farmaceutico Thu, 14 May 2020 18:06:33 +0000 it-IT hourly 1 https://wordpress.org/?v=6.9.4 https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg parco eolico - Le Fonti New Pharma Italy https://www.newpharmaitaly.it/tag/parco-eolico/ 32 32 Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy  https://www.newpharmaitaly.it/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-spain-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy/ https://www.newpharmaitaly.it/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-spain-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy/#respond Thu, 14 May 2020 18:06:33 +0000 https://www.adnkronos.com/immediapress/chimica-e-farmacia/2020/05/14/akcea-announces-approval-for-reimbursement-tegsedi-inotersen-spain-for-treatment-hereditary-transthyretin-amyloidosis-with-polyneuropathy_U3rp2WeGsLOtKh25IDgN7K.html TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection Approval Issued by Ministry of Health of Spain Only Six Months After Submission BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of...

L'articolo Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy  proviene da Le Fonti New Pharma Italy.

]]> https://www.newpharmaitaly.it/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-spain-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy/feed/ 0